Please note: This is for information only.
Refer to local guidelines for treatment recommendations.
- A new oxazolidinone antibiotic
- Excellent bioavailability when given orally.
- Usual adult dose: 600mg twelve hourly – oral or IV
- Usual duration 10-14 days not advised for treatment of longer that 28 days.
- No dosage reduction necessary if renal impairment
- A reversible, non-selective inhibitor of monoamine oxidase. Has no antidepressive activity at antibacterial doses.
Precautions (for complete list see manufacturer's datasheet.)
- Patients should be advised to avoid ingesting excessive amounts of food and drinks with a high tyramine content (e.g. mature cheese, yeast extracts, undistilled alcoholic beverages and fermented soya bean products such as soy sauce).
- Close monitoring of blood pressure required if taking MAOIs, SSRIs, TCAs, dopaminergics, pethidine, or if patient has uncontrolled hypertension, thyrotoxicosis, bipolar depressive disorder or schizophrenia.
- Check full blood count weekly for all patients during therapy – myelosuppression possible.
- Patients should be advised to report any visual impairment such as changes in acuity, colour vision or field defects. Patients who require >28 days therapy should have regular formal visual assessments. Treatment may only be continued beyond 28 days on the advice of a Consultant and the rationale for extended treatment should be clearly documented in the patient's medical record.
- Patients should be advised to report any signs of neuropathy, anaemia, thrombocytopenia or lactic acidosis.
- Microbiology advice only– restricted agent
- Resistant enterococcal infections (VRE).
- Resistant staphylococcal infections.
Active against most strains of:
- Staphylococcus aureus – including MRSA
Not active against most strains of:
- Haemophilus influenzae
- Neisseria spp
- E coli